Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Top Cited Papers
- 30 September 2013
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 112 (12), 1980-1984
- https://doi.org/10.1016/j.amjcard.2013.08.026
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Use and Misuse of Multivariable Approaches in Interventional Cardiology Studies on Drug‐Eluting Stents: A Systematic ReviewJournal of Interventional Cardiology, 2012
- Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studiesPediatric Blood & Cancer, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapyLeukemia & Lymphoma, 2008
- The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclinesBreast Cancer Research and Treatment, 2007
- Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter?Journal of Clinical Oncology, 2007
- Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer SurvivorsJournal of Clinical Oncology, 2007
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005